iN Therapeutics is a biotechnology platform specializing in drug development targeting ion channels to create therapies for patients with incurable neurological diseases, including chronic pain and amyotrophic lateral sclerosis. The company utilizes a proprietary ion channel compound library and electrophysiological research techniques to address the unmet medical needs of these conditions.
Funding
$34.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many neurological diseases, such as chronic pain and amyotrophic lateral sclerosis (ALS), lack effective treatments, creating a significant unmet need for patients suffering from these conditions. Developing drugs for these diseases is challenging due to the complexity of the nervous system and the limited number of drug targets.
Solution
iN Therapeutics is a biotechnology company focused on developing novel therapies for incurable neurological diseases by targeting ion channels. The company utilizes a proprietary ion channel compound library and electrophysiological research techniques to discover and develop new drugs. iN Therapeutics employs a one-stop evaluation platform, including target compound identification, compound synthesis, efficacy evaluation, and validation. The company's platform, VITVO, houses all the patch-clamp equipment needed for research.
Target Audience
The primary target audience includes patients suffering from incurable neurological diseases, as well as pharmaceutical companies seeking novel drug candidates and research tools for ion channel-related drug discovery.
Features
- Proprietary ion channel compound library
- Electrophysiological research techniques for drug discovery
- One-stop evaluation platform for ion channel-targeted drug development
- VITVO platform equipped with comprehensive patch-clamp equipment
- Specialized medicinal chemistry team focused on ion channel targets
- Pipeline of drug candidates targeting various neurological diseases, including chronic pain, noise-induced hearing loss, ALS and epilepsy